Immunic, Inc (NASDAQ:IMUX) announced it strengthened its leadership team on Wednesday as the company prepares to advance its multiple sclerosis pipeline through late-stage development and potential commercialization.
Immunic Appoints Erik Lundgren As CEO
Immunic named biopharmaceutical executive Erik Lundgren as CEO effective May 22, 2026, with his employment beginning June 1.
Lundgren succeeds Daniel Vitt, Ph.D., who will continue overseeing scientific strategy and portfolio advancement while remaining on Immunic's board of directors.
Company Advances Late-Stage Multiple Sclerosis Programs
